Zealand Pharma A/S (OTCMKTS:ZLDPF – Free Report) – Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Zealand Pharma A/S in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will earn $7.74 per share for the year. The consensus estimate for Zealand Pharma A/S’s current full-year earnings is ($2.19) per share.
Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.10. The firm had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $248.61 million. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative return on equity of 15.24%.
Check Out Our Latest Stock Analysis on ZLDPF
Zealand Pharma A/S Stock Performance
ZLDPF opened at $74.13 on Thursday. The firm’s fifty day simple moving average is $66.46 and its two-hundred day simple moving average is $85.71. Zealand Pharma A/S has a 52-week low of $57.97 and a 52-week high of $141.74. The company has a market cap of $5.26 billion, a price-to-earnings ratio of -31.41 and a beta of 0.74. The company has a quick ratio of 35.49, a current ratio of 35.49 and a debt-to-equity ratio of 0.03.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Featured Articles
- Five stocks we like better than Zealand Pharma A/S
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- How to trade penny stocks: A step-by-step guide
- 3 Stocks Set to Double—And There’s Still Time to Buy
- 3 Warren Buffett Stocks to Buy Now
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
